Rhythm Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Rhythm Pharmaceuticals
RYTM Stock  USD 101.02  3.56  3.65%   
Rhythm Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Rhythm Pharmaceuticals' valuation are provided below:
Gross Profit
155.9 M
Profit Margin
(1.10)
Market Capitalization
6.7 B
Enterprise Value Revenue
37.1507
Revenue
174.3 M
There are over one hundred nineteen available trending fundamental ratios for Rhythm Pharmaceuticals, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to check out Rhythm Pharmaceuticals' recent fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 11th of January 2026, Market Cap is likely to grow to about 2.5 B. Also, Enterprise Value is likely to grow to about 2.4 B

Rhythm Pharmaceuticals Total Revenue

157.13 Million

Check Rhythm Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rhythm Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 11.9 M or Selling General Administrative of 174.2 M, as well as many indicators such as Price To Sales Ratio of 28.67, Dividend Yield of 9.0E-4 or PTB Ratio of 19.61. Rhythm financial statements analysis is a perfect complement when working with Rhythm Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Rhythm Stock
Check out the analysis of Rhythm Pharmaceuticals Correlation against competitors.
To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.

Rhythm Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets473.7 M451.1 M199.7 M
Slightly volatile
Other Current Liabilities123 M117.2 M29.3 M
Slightly volatile
Total Current Liabilities139.5 M132.8 M35.9 M
Slightly volatile
Property Plant And Equipment Net2.5 M4.7 M2.1 M
Slightly volatile
Accounts Payable14.9 M14.2 M5.5 M
Slightly volatile
Cash54.5 M102.5 M48.5 M
Slightly volatile
Non Current Assets Total21.8 M20.8 M9 M
Slightly volatile
Non Currrent Assets Other5.1 M9 M4.2 M
Slightly volatile
Cash And Short Term Investments387.1 M368.6 M174.1 M
Slightly volatile
Common Stock Total Equity36.4 K64.4 K32.9 K
Slightly volatile
Common Stock Shares Outstanding42 M70.1 M41.7 M
Slightly volatile
Short Term Investments152.7 M266.1 M115.5 M
Slightly volatile
Liabilities And Stockholders Equity473.7 M451.1 M199.7 M
Slightly volatile
Non Current Liabilities Total135.5 M129 M47.2 M
Slightly volatile
Other Current Assets19.8 M18.8 M7.3 M
Slightly volatile
Other Stockholder Equity1.4 B1.4 B520.6 M
Slightly volatile
Total Liabilities275 M261.9 M83.1 M
Slightly volatile
Property Plant And Equipment Gross10.7 M10.2 M3.4 M
Slightly volatile
Total Current Assets451.8 M430.3 M190.7 M
Slightly volatile
Common Stock53.1 K70.2 K44.5 K
Slightly volatile
Capital Surpluse1.2 B1.1 B484.3 M
Slightly volatile
Current Deferred Revenue1.1 M1.2 M4.7 M
Pretty Stable
Other Assets20.5 M19.5 M6.9 M
Slightly volatile
Deferred Long Term Liabilities91.5 M87.2 M37.8 M
Slightly volatile
Long Term Investments10.5 M19.2 M8.9 M
Slightly volatile
Short Term Debt932.7 K1.4 M1.7 M
Slightly volatile
Property Plant Equipment2.3 M2.5 M1.5 M
Slightly volatile
Other Liabilities93.2 M88.7 M38.1 M
Slightly volatile
Net Invested Capital18.6 M19.6 M154.7 M
Pretty Stable
Net Working Capital264.3 M297.5 M205.4 M
Slightly volatile
Capital Stock172.5 M164.3 M28.3 M
Slightly volatile
Short and Long Term Debt Total2.2 M3.5 M3.2 M
Slightly volatile
Capital Lease Obligations2.2 M3.5 M3.2 M
Slightly volatile
Long Term Debt Total1.1 M1.2 M1.3 M
Slightly volatile

Rhythm Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.3 M1.8 M1.1 M
Pretty Stable
Selling General Administrative174.2 M165.9 M52.9 M
Slightly volatile
Other Operating Expenses477.7 M455 M145.8 M
Slightly volatile
Research Development287.3 M273.7 M89.2 M
Slightly volatile
Total Operating Expenses461.6 M439.6 M142.4 M
Slightly volatile
Interest Income17.8 M16.9 M4.7 M
Slightly volatile
Reconciled Depreciation1.2 M1.8 M757.3 K
Slightly volatile

Rhythm Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow47.6 M69.5 M41.4 M
Slightly volatile
Depreciation1.9 M1.8 M736.9 K
Slightly volatile
End Period Cash Flow54.7 M103 M48.7 M
Slightly volatile
Stock Based Compensation47.9 M45.6 M14.5 M
Slightly volatile
Sale Purchase Of Stock119.9 M162.7 M92.7 M
Slightly volatile
Change To Netincome24.6 M23.4 M10.1 M
Slightly volatile
Issuance Of Capital Stock116.5 M160.2 M152.9 M
Slightly volatile
Net Borrowings57.9 M65.1 M71.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio28.6730.18122
Slightly volatile
Dividend Yield9.0E-40.0010.0011
Slightly volatile
Days Sales Outstanding92.659.71106
Slightly volatile
Stock Based Compensation To Revenue0.330.354.7881
Slightly volatile
Capex To Depreciation0.02920.03073.8439
Slightly volatile
EV To Sales30.0731.66109
Slightly volatile
Inventory Turnover0.780.824.0518
Slightly volatile
Days Of Inventory On Hand283461171
Slightly volatile
Payables Turnover1.020.980.3788
Slightly volatile
Research And Ddevelopement To Revenue2.02.124.026
Slightly volatile
Capex To Revenue7.0E-47.0E-41.227
Slightly volatile
Cash Per Share3.254.733.6122
Slightly volatile
Days Payables Outstanding3683873.3 K
Slightly volatile
Income Quality0.480.50.896
Pretty Stable
Intangibles To Total Assets0.01430.01420.015
Slightly volatile
Current Ratio2.772.927.7906
Pretty Stable
Receivables Turnover3.826.333.7124
Slightly volatile
Debt To Equity1.471.40.2705
Slightly volatile
Capex Per Share7.0E-47.0E-40.0232
Pretty Stable
Revenue Per Share2.021.920.5078
Slightly volatile
Interest Debt Per Share4.294.090.8484
Slightly volatile
Debt To Assets0.620.590.1184
Slightly volatile
Operating Cycle351507274
Slightly volatile
Days Of Payables Outstanding3683873.3 K
Slightly volatile
Ebt Per Ebit1.051.130.9765
Very volatile
Long Term Debt To Capitalization0.320.360.3902
Slightly volatile
Total Debt To Capitalization0.580.550.1121
Slightly volatile
Debt Equity Ratio1.471.40.2705
Slightly volatile
Quick Ratio2.632.777.7504
Pretty Stable
Net Income Per E B T0.780.90.9548
Pretty Stable
Cash Ratio0.840.892.932
Slightly volatile
Days Of Inventory Outstanding283461171
Slightly volatile
Days Of Sales Outstanding92.659.71106
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.151.0258
Slightly volatile
Fixed Asset Turnover15.1828.57.5037
Slightly volatile
Debt Ratio0.620.590.1184
Slightly volatile
Price Sales Ratio28.6730.18122
Slightly volatile
Asset Turnover0.310.30.0795
Slightly volatile
Gross Profit Margin0.70.810.8187
Pretty Stable

Rhythm Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.5 B2.4 B1.3 B
Slightly volatile
Enterprise Value2.4 B2.3 B1.2 B
Slightly volatile

Rhythm Fundamental Market Drivers

Rhythm Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Rhythm Pharmaceuticals Financial Statements

Rhythm Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Rhythm Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.2 M1.1 M
Total Revenue149.6 M157.1 M
Cost Of Revenue15.4 M16.1 M
Stock Based Compensation To Revenue 0.35  0.33 
Research And Ddevelopement To Revenue 2.10  2.00 
Revenue Per Share 1.92  2.02 
Ebit Per Revenue(1.84)(1.93)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Rhythm Pharmaceuticals is a strong investment it is important to analyze Rhythm Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rhythm Pharmaceuticals' future performance. For an informed investment choice regarding Rhythm Stock, refer to the following important reports:
How To Invest In Rhythm
Details
Is Rhythm Stock a good investment?
Details
What is Rhythm Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Rhythm Pharmaceuticals Correlation against competitors.
To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.10)
Revenue Per Share
2.739
Quarterly Revenue Growth
0.543
Return On Assets
(0.27)
Return On Equity
(0.86)
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY